Recombinant human arginase Toxicity in mice is reduced by citrulline supplementation

Translational Oncology

Volumn 5, Issue 1, 2012, Pages 26-31

  Mauldin, Jeremy P ^a   Zeinali, Ideen ^a   Kleypas, Keri ^a   Woo, Jung Hee ^a   Blackwood, Rebecca S ^a   Jo, Chan Hee ^b   Stone, Everett M ^c   Georgiou, George ^c   Frankel, Arthur E ^a  

^a SCOTT AND WHITE MEMORIAL HOSPITAL   (United States)

^b TEXAS A AND M HEALTH SCIENCE CENTER   (United States)

^c The University of Texas at Austin   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; ARGININE; CITRULLINE; RECOMBINANT ARGINASE I COBALT COUPLED TO POLYETHYLENE GLYCOL 5000; RECOMBINANT ENZYME; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; AUTOPSY; BLOOD CELL COUNT; BODY WEIGHT DISORDER; BONE MARROW NECROSIS; CONTROLLED STUDY; DOSE LIMITING TOXICITY; DRUG CYTOTOXICITY; DRUG TOXICITY; FEMALE; HISTOLOGY; IN VIVO STUDY; MAXIMUM TOLERATED DOSE; MOUSE; NONHUMAN; PHARMACOLOGICAL PARAMETERS; SURVIVAL; WEIGHT REDUCTION;

EID: 84856008075     PISSN: None     EISSN: 19365233     Source Type: Journal    
DOI: 10.1593/tlo.11262     Document Type: Article

References (16)

1. Feun LG, You M, Wu C, Kuo MT, Waugpaichitr M, Spector S, and Savaraj N (2008). Arginine deprivation as a targeted therapy for cancer. Curr Pharm Design 14, 1049-1057.
2. Yau CC, Chan P, Pang R, Chan W, Cheng PN, and Poon R (2010). A phase I study of recombinant human arginase (rhArgI) for patients with advanced hepatocellular carcinoma. J Clin Oncol 28(suppl), e13503.
3. Feun LG, You M, Wu C, Wangpaichitr M, Kuo MT, Marini A, Jungbluth A, and Savaraj N (2010). Final results of phase II trial of pegylated arginine deiminase (ADI-PEG20) in metastatic melanoma (MM). J Clin Oncol 28(suppl), 15s.
4. Stone EM, Glazer E, Chantranupong L, Cherukuri P, Breece RM, Tierney DL, Curley SA, Iverson BL, and Georgiou G (2010). Replacing Mn(2+) with Co(2+) in human arginase I enhances cytotoxicity toward L-arginine auxotrophic cancer cell lines. ACS Chem Biol 5, 333-342.
5. Agrawal V, Woo JH, Mauldin JP, Jo C, Stone EM, Georgiou G, and Frankel AE (2012). Cytotoxicity of human recombinant arginase I [Co]-PEG5000 in the presence of supplemental L-citrulline is dependent on decreased argininosuccinate synthetase expression in human cells. Anticancer Drugs 23, 51-64.
6. Glazer ES, Stone EM, Zhu C, Massey KL, Hamir AN, and Curley SA (2011). Bioengineered human arginase I with enhanced activity and stability controls hepatocellular and pancreatic carcinoma xenografts. Transl Oncol 4, 138-146.
7. Wu G and Meininger CJ (2008). Analysis of citrulline, arginine, and methylarginines using high-performance liquid chromatography. Methods Enzymol 440, 177-189.
8. Ascierto PA, Scala S, Castello G, Daponte A, Simeone E, Ottaiano A, Beneduce G, De Rosa V, Izzo F, Melucci MT, et al. (2005). Pegylated arginine deiminase treatment of patients with metastatic melanoma: results from phase I and II studies. J Clin Oncol 23, 7660-7668.
9. Glazer ES, Piccirillo M, Albino V, Di Giacomo R, Palaia R, Mastro AA, Beneduce G, Castello G, De Rosa V, Petrillo A, et al. (2010). Phase II study of pegylated arginine deiminase for nonresectable and metastatic hepatocellular carcinoma. J Clin Oncol 28, 2220-2226.
10. Feun L and Savaraj N (2006). Pegylated arginine deiminase: a novel anticancer enzyme agent. Exp Opin Invest Drugs 15, 815-822.
11. Harder U, Koletzko B, and Peissner W (2011). Quantification of 22 plasma amino acids combining derivatization and ion-pair LC-MS/MS. J Chromatogr B Analyt Technol Biomed Life Sci 879, 495-504.
12. Cormio L, De Siati M, Lorusso F, Selvaggio O, Mirabella L, Sanguedolce F, and Carrieri G (2011). Oral L-citrulline supplementation improves erection hardness in men with mild erectile dysfunction. Urology 77, 119-122.
13. Orozco-Gutierrez JJ, Castillo-Martinez L, Orea-Tejeda A, Vazquez-Diaz O, Valdespino-Trejo A, Narvaez-David R, Keirns-Davis C, Carrasco-Ortiz O, Navarro-Navarro A, and Sanchez-Santillan R (2010). Effect of L-arginine or L-citrulline oral supplementation on blood pressure and right ventricular function in heart failure patients with preserved ejection fraction. Cardiol J 17, 612-618.
14. Ochiai M, Hayashi T, Morita M, Ina K, Maeda M, Watanabe F, and Morishita K (2010). Short-term effects of L-citrulline supplementation on arterial stiffness in middle-aged men. Int J Cardiol, E-pub ahead of print November 8.
15. Kameda N, Okigawa T, Kimura T, Fujibayashi M, Asada T, Kinoshita R, Baba S, Morita M, Morishita K, and Moritani T (2011). The effect of L-citrulline ingestion on ECG QT interval and autonomic nervous system activity. J Physiol Anthropol 30, 41-45.
16. Thibault R, Flet L, Vavasseur F, Lemerle M, Ferchaud-Roucher V, Picot D, and Darmaun D (2011). Oral citrulline does not affect whole body protein metabolism in healthy human volunteers: results of a prospective, randomized, doubleblind, cross-over study. Clin Nutr 30, 807-811.